Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins

(Impact Journals LLC) Oncotarget recently published " A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion, featuring different arrangements of antibody and IL2.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news